CTRI/2009/091/000154OtherPhase 2
A Phase 2a, Multicentre, Double Blind , Randomized , Active controlled , Parallel arm clinical study to study the Efficacy and Safety of Mk-0941 Compared to sulphonylureas in Patients with Type 2 Diabetes Mellitus With Inadequate Glycemic control on Metformin therapy.
Merck Sharp and Dohme0 sites130 target enrollmentStarted: TBDLast updated:
Trial Snapshot
- Phase
- Phase 2
- Status
- Other
- Sponsor
- Enrollment
- 130
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •Patient has type 2 diabetes mellitus
- •Between the ages of 18 and 70
Exclusion Criteria
- •Patient has a history of type 1 Diabetes Mellitus or ketoacidosis.
- •Patient is on a weight loss program and is not in the maintenance phase or is taking weight loss medication.
- •Patient has had surgery within 30 days of starting the study or has planned major surgery during the study
Investigators
Similar Trials
Active, not recruiting
Phase 1
A Phase 2a Multicenter, Randomized, Double Blind, Parallel, Proof of concept Study Evaluating the Efficacy and Safety of Nipocalimab and Certolizumab Combination Therapy in Participants with Active Rheumatoid Arthritis despite Prior Treatment with Advanced Therapies (bDMARD or tsDMARD)Rheumatoid ArthritisCTIS2023-504045-31-00Janssen - Cilag International85
Active, not recruiting
Phase 1
A study of PQ912 in patients with Alzheimer's Disease.Early Stage Alzheimer's DiseaseMedDRA version: 19.0Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 19.0Level: PTClassification code 10074616Term: Prodromal Alzheimer's diseaseSystem Organ Class: 10029205 - Nervous system disordersEUCTR2014-001967-11-NLProbiodrug AG110
Active, not recruiting
Phase 1
A study of PQ912 in patients with Alzheimer's Disease.Early Stage Alzheimer's DiseaseMedDRA version: 18.1Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 18.1Level: PTClassification code 10074616Term: Prodromal Alzheimer's diseaseSystem Organ Class: 10029205 - Nervous system disordersEUCTR2014-001967-11-SEProbiodrug AG110
Active, not recruiting
Phase 1
A study of PQ912 in patients with Alzheimer's Disease.Early Stage Alzheimer's DiseaseMedDRA version: 19.0Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 19.0Level: PTClassification code 10074616Term: Prodromal Alzheimer's diseaseSystem Organ Class: 10029205 - Nervous system disordersEUCTR2014-001967-11-DEProbiodrug AG110
Completed
Phase 2
A Phase 2A Multicenter, Randomized, Double Blind, Placebo-Controlled, Parallel-Group Safety and Tolerability Trial of PQ912 in Subjects with early Alzheimer's DiseaseAlzheimer's disease10057167DementiaNL-OMON44623Probiodrug AG10